A case of pembrolizumab-induced pigmented purpuric dermatosis

A case of pembrolizumab-induced pigmented purpuric dermatosis

Bibliographic Details
Main Authors:	Oluwaseun J. Oyeku, BS, Drew Mitchell, MD, Hillary Elwood, MD, John Durkin, MD
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	JAAD Case Reports
Subjects:	capillaritis immune-related adverse events iRAE immune checkpoint inhibitors PD-1 PD-1 inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512623000620

Similar Items

Pembrolizumab‐induced acquired perforating dermatosis
by: Yaron Gu, et al.
Published: (2024-12-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
by: Ryunosuke Hoshi, et al.
Published: (2024-09-01)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
by: Guili Huang, et al.
Published: (2022-11-01)

Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis
by: Roxana Schwab, et al.
Published: (2024-02-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report
by: Benjamin Kiaei, et al.
Published: (2024-06-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
by: Emily Allen, et al.
Published: (2023-10-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
by: Alberto Bongiovanni, et al.
Published: (2021-05-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
by: Virginia Liberini, et al.
Published: (2021-04-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023-12-01)

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
by: Yu CW, et al.
Published: (2020-11-01)

Association between history of viral infections and melanoma mortality
by: Nathan Shen, et al.
Published: (2024-11-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01)

The role of immune checkpoints in cardiovascular disease
by: Laura I. Yousif, et al.
Published: (2022-10-01)

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
by: Shabnam Shaabani, et al.
Published: (2022-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience
by: Paola Parente, et al.
Published: (2022-03-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Severe lichenoid eruption due to concomitant medications following nivolumab administration
by: Risa Kakuta, et al.
Published: (2023-09-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
by: Xingxiang Pu, et al.
Published: (2018-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
by: Jiaxin Zhou, et al.
Published: (2022-07-01)

PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
by: Cuiping Lin, et al.
Published: (2022-08-01)

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01)

Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis
by: Tao Huang, et al.
Published: (2022-12-01)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
by: Charissa A. C. Jessurun, et al.
Published: (2017-09-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
by: Lorenz Kocheise, et al.
Published: (2024-01-01)

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
by: Lorenz Kocheise, et al.
Published: (2024-01-01)

Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient
by: Zofia Kachlik, et al.
Published: (2024-08-01)

Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research
by: Ritesh Kumar, et al.
Published: (2023-07-01)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
by: Areti Strati, et al.
Published: (2023-06-01)